Outcome for Neoadjuvant Treatment of Parotid Gland Adamantinoma-Like Ewing Sarcoma: Case Report and Review of Literatures. (October 2022)

• Record Type: Journal Article
• Authors: Wei, Christina H.; Thompson, Lester D. R.; Lee, Kyle; Chow, Warren; Liang, Yu
• Is Part Of: International journal of surgical pathology. Volume 30:Number 7(2022)
• Page Start: 776
• Page End: 783
• Publication Date: 2022-10
• Subjects: adamantinoma-like -- ewing sarcoma -- t(11;22) -- EWSR1::FLI1 -- head and neck -- neoadjuvant therapy; Pathology, Surgical -- Periodicals; 617.07
• DOI: 10.1177/10668969221081029
• Languages: English
• ISSNs: 1066-8969

Abstract

Adamantinoma-like Ewing sarcoma typically shows t(11;22) EWSR1::FLI1 translocation and complex epithelial differentiation. It poses a diagnostic challenge, especially in the head and neck region, due to its under-recognition and significant histologic overlap with other malignancies. Neoadjuvant and adjuvant treatment information on head and neck Adamantinoma-like Ewing sarcoma is limited. Herein, we report a case of a 78-year-old female with Adamantinoma-like Ewing sarcoma of the parotid gland, including the imaging findings and clinical response to neoadjuvant therapy followed by surgery. The efficacy of neoadjuvant therapy in the treatment of Adamantinoma-like Ewing sarcoma is discussed in the context of a review of pertinent literature. Adamantinoma-like Ewing sarcoma in the head and neck is frequently misdiagnosed as poorly differentiated squamous cell carcinoma or a basaloid salivary gland carcinoma. Adamantinoma-like Ewing sarcoma is a EWS1::FLI1 translocation driven tumor; frequently misdiagnosed on head and neck biopsies as poorly differentiated carcinoma, or squamous cell carcinoma. Ewing sarcoma-specific chemoregimen appears effective for this entity. If diagnosed early, patient may be amenable to neoadjuvant therapy, which may improve surgical and cosmetic outcomes. This is especially important in head and neck regions.